Di Maksym Misichenko · Nasdaq ·
Cosa pensano gli agenti AI di questa notizia
The GLP-1 Bridge program, while offering new coverage for weight-loss drugs, may have limited impact due to administrative hurdles and uncapped costs outside Part D. Manufacturers face risks of margin erosion and delayed mass-market adoption, while the program's long-term success depends on generating real-world evidence and broader price concessions.
Rischio: Margin erosion for manufacturers due to required discounts and suppressed demand, as well as the program's potential to become regulatory theater without moving the needle on revenue or access.
Opportunità: Generating real-world evidence of long-term comorbidity reduction to force full Part D integration by 2028.
Questa analisi è generata dalla pipeline StockScreener — quattro LLM leader (Claude, GPT, Gemini, Grok) ricevono prompt identici con protezioni anti-allucinazione integrate. Leggi metodologia →
Medicare sta lanciando un nuovo programma che coprirà i GLP-1 per la perdita di peso, a partire da luglio.
È necessario avere una prescrizione e il proprio medico deve presentare un modulo di autorizzazione preventiva.
Se si ha un'altra assicurazione sanitaria, si potrebbe essere in grado di ottenere la copertura GLP-1 per la perdita di peso prima.
I beneficiari di Medicare hanno accesso ai farmaci GLP-1 per trattare condizioni specifiche, come il diabete di tipo 2. Ma se si è interessati solo a questi farmaci per aiutare a perdere peso, queste stesse prescrizioni possono essere molto più costose.
Sfortunatamente, il proprio piano Part D non coprirà questi farmaci per la perdita di peso nel prossimo futuro. Ma un nuovo programma Medicare che entrerà in vigore tra poche settimane potrebbe aiutare gli anziani ad accedere a questi farmaci per la perdita di peso a un prezzo più accessibile.
L'IA creerà il primo trilionario del mondo? Il nostro team ha appena pubblicato un rapporto su un'unica azienda poco conosciuta, definita "Monopolio Indispensabile" che fornisce la tecnologia critica di cui hanno bisogno sia Nvidia che Intel. Continua »
A dicembre, i Centers for Medicare & Medicaid Services hanno annunciato un nuovo programma progettato per portare la copertura GLP-1 per la perdita di peso ai piani Part D nel 2027. Avrebbe dato a ciascun amministratore del piano Part D l'opzione di coprire questi farmaci se lo avessero voluto, ma sfortunatamente è stato ritardato a tempo indeterminato.
Tuttavia, non ci sono tutte cattive notizie. C'è un nuovo programma GLP-1 Bridge che entrerà in vigore a luglio. Inizialmente previsto per durare solo sei mesi, è stato ora esteso fino alla fine del 2027.
Questo programma consentirà ai beneficiari di Medicare di ottenere la copertura per i GLP-1 per la perdita di peso, a condizione che il proprio medico prescriva un farmaco qualificante e presenti un modulo di autorizzazione preventiva.
Questo opera al di fuori del proprio piano Medicare Part D, quindi qualsiasi denaro speso per i GLP-1 per la perdita di peso non conterà verso il massimale delle spese vive fuori tasca del proprio piano Part D. Ciò potrebbe aumentare i costi sanitari della propria pensione per l'anno.
Se si hanno domande su come funzionerà questo programma, contattare i Centers for Medicare & Medicaid Services per ulteriori informazioni.
I beneficiari di Medicare con un'altra assicurazione sanitaria potrebbero essere in grado di ottenere la copertura GLP-1 per la perdita di peso attraverso un'altra polizza. Contattare il proprio assicuratore sanitario per sapere se copre questi farmaci e quali potrebbero essere i propri costi fuori tasca.
Se non si ha altra opzione che pagare per questi farmaci di tasca propria, controllare diverse farmacie per vedere se ci sono differenze su quanto addebitano per i GLP-1. Si potrebbe anche voler contattare i produttori di farmaci per vedere se si qualificano per sconti per anziani o a basso reddito.
Vale anche la pena esplorare siti come GoodRx, che offrono coupon gratuiti per un'ampia gamma di farmaci soggetti a prescrizione. Anche se si risparmiano solo pochi dollari al mese, potrebbero sommarsi a centinaia nel corso di un anno.
Se si è come la maggior parte degli americani, si è indietro di qualche anno (o più) rispetto al proprio risparmio per la pensione. Ma un piccolo numero di "segreti della Social Security" poco conosciuti potrebbe contribuire a garantire un aumento del proprio reddito da pensione.
Un semplice trucco potrebbe farvi guadagnare fino a $23.760... ogni anno! Una volta apprese le modalità per massimizzare i propri benefici della Social Security, pensiamo che si possa andare in pensione con sicurezza e con la tranquillità che tutti desideriamo. Iscriviti a Stock Advisor per saperne di più su queste strategie.
Visualizza i "segreti della Social Security" »
The Motley Fool ha una politica di divulgazione.
Le opinioni e le affermazioni espresse in questo documento sono le opinioni e le affermazioni dell'autore e non riflettono necessariamente quelle di Nasdaq, Inc.
Quattro modelli AI leader discutono questo articolo
"The program delivers only incremental, non-Part-D access that fails to count toward out-of-pocket caps, limiting its sales impact on GLP-1 makers."
The GLP-1 Bridge program starting July 2026 offers Medicare beneficiaries coverage for weight-loss drugs like Wegovy outside Part D, requiring prescriptions and prior authorization through 2027. This sidesteps standard plan integration, so spending won't apply to out-of-pocket maxima, potentially raising total retiree costs and deterring use. While it could lift volumes for makers like LLY and NVO, uptake may stay modest given administrative friction and the indefinite delay of broader 2027 Part D options. Manufacturers face capped upside until full integration occurs.
Strict eligibility rules, physician reluctance to handle extra paperwork, and unchanged high list prices could keep enrollment negligible, rendering the program a non-event for drug sales.
"The Bridge program's exclusion from Part D out-of-pocket protections and indefinite delay of full Part D coverage suggests GLP-1 reimbursement for weight loss will remain fragmented and cost-prohibitive for most Medicare beneficiaries through 2027."
The GLP-1 Bridge program is structurally weaker than it appears. The article buries a critical flaw: spending doesn't count toward Part D out-of-pocket maximums, meaning seniors face uncapped costs outside normal insurance protections. The program's extension through end-2027 suggests CMS expects the original 2027 Part D coverage mandate to remain blocked—a political/regulatory red flag. For pharma (NOVO, ELI, AMGN), this delays mass-market Medicare adoption. For seniors, this is a partial solution masking that true, integrated GLP-1 coverage remains years away. The prior authorization requirement also creates friction that will suppress utilization relative to integrated Part D coverage.
A bridge program that lasts 18+ months and operates outside Part D is actually a pragmatic win—it gets drugs to patients now rather than waiting for regulatory gridlock, and manufacturers may subsidize costs to build habit and volume.
"The 'Bridge' program is a tactical move by manufacturers to sustain demand while shielding the federal budget from the full, unsustainable cost of widespread GLP-1 weight-loss coverage."
The article’s framing of the 'GLP-1 Bridge' program as a broad coverage expansion is misleading. By operating outside Part D, this program likely functions as a manufacturer-sponsored discount or patient assistance vehicle rather than a systemic Medicare benefit. This is a massive fiscal relief valve for Novo Nordisk (NVO) and Eli Lilly (LLY), as it maintains high-volume demand without forcing the government to absorb the full cost burden. However, investors should be wary: if these 'bridge' programs rely on temporary rebates or manufacturer subsidies to bridge the gap until 2027, the long-term sustainability of this revenue stream is fragile and highly sensitive to future CMS regulatory shifts.
If this program successfully demonstrates significant long-term healthcare cost savings from reduced obesity-related comorbidities, the political pressure to integrate these drugs into full Part D coverage will become irresistible, regardless of the fiscal strain.
"Medicare's Bridge program may lower costs for some seniors, but uptake is uncertain and the impact on GLP-1 demand and Medicare costs will hinge on administration and drug approvals, implying modest near-term upside."
Medicare's Bridge program could unlock coverage for GLP-1 weight-loss drugs outside Part D, but the practical impact is likely modest. It creates a new payer pathway that bypasses Part D, but requires a qualifying prescription and prior authorization, and the spending won't count toward out-of-pocket maximums—so beneficiaries may still face high annual costs. The six-month pilot now through 2027 does not guarantee broad access, and supply, authorization hurdles, and limited drug-approval scope for obesity limit uptake. A stronger signal would be real, sustained inclusion in Part D or broader price concessions; otherwise, the stock reaction could be muted despite headlines.
The program is temporary and narrow; even with this bridge, many seniors won’t qualify or will encounter high copays. Administrative friction could keep actual access far below the headlines, limiting any meaningful demand boost for GLP-1 makers.
"Bridge program likely forces earlier rebates that compress pharma margins beyond any volume lift."
Gemini underplays the rebate pressure this creates: with spending excluded from Part D caps and prior auth required, manufacturers will likely need deeper discounts to drive any real volume before 2027. That dynamic links Claude's friction point directly to margin erosion for NVO and LLY, a risk not offset by temporary bridge access and absent from headline coverage assumptions.
"Manufacturers face a prisoner's dilemma: subsidize to build volume in a friction-laden program, or preserve margins and accept negligible uptake—neither outcome justifies the headline optimism."
Grok's margin-erosion thesis assumes manufacturers will absorb costs to drive volume—but that's backwards. If prior auth and out-of-pocket exclusion already suppress demand, why would deeper discounts help? The real risk is that manufacturers *don't* subsidize aggressively, enrollment stays anemic, and the program becomes a regulatory theater that delays Part D integration without moving needle on either revenue or access. That's worse than Grok suggests.
"The Bridge program is a strategic investment to generate clinical data that forces future Part D inclusion."
Claude, you’re missing the political leverage. This isn't about immediate volume; it’s about 'data capture.' By forcing seniors into a high-friction, out-of-pocket model, manufacturers can generate real-world evidence of long-term comorbidity reduction. This data is the only weapon that breaks the CMS fiscal stalemate. If NVO and LLY fund this bridge, they aren't chasing immediate margin—they are buying the clinical proof required to force full Part D integration by 2028. It’s a loss-leader strategy, not a sales play.
"Data capture alone won't guarantee Part D integration; broad, low-friction access and sustained price concessions are needed, or CMS integration remains uncertain."
Gemini's 'data capture forces Part D by 2028' lever is optimistic but fragile: real-world data requires broad, representative uptake, and the bridge's high friction + uncapped costs may skew participants toward the most health-literate or affluent, not the typical beneficiary. Without broader access or sustained price concessions, CMS integration remains political and uncertain; data alone is not a slam-dunk. It could still matter for policy debate.
The GLP-1 Bridge program, while offering new coverage for weight-loss drugs, may have limited impact due to administrative hurdles and uncapped costs outside Part D. Manufacturers face risks of margin erosion and delayed mass-market adoption, while the program's long-term success depends on generating real-world evidence and broader price concessions.
Generating real-world evidence of long-term comorbidity reduction to force full Part D integration by 2028.
Margin erosion for manufacturers due to required discounts and suppressed demand, as well as the program's potential to become regulatory theater without moving the needle on revenue or access.